Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: Comparison study

Virology Journal

Volumn 10, Issue , 2013, Pages

  El Fakharany, Esmail M ^a   Sánchez, Lourdes ^b   Al Mehdar, Hussein A ^c   Redwan, Elrashdy M ^a,c  

^a Universities and Research Institutes District   (Egypt)

^b UNIVERSIDAD DE ZARAGOZA   (Spain)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Anti infectivity; Comparison; Different lactoferrin; Hepatitis C virus

Indexed keywords

LACTOFERRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; COW; FLOW CYTOMETRY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LATENT VIRUS INFECTION; NONHUMAN; PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CAMELS; CATTLE; EGYPT; FEMALE; HEP G2 CELLS; HEPACIVIRUS; HEPATOCYTES; HUMANS; LACTOFERRIN; PROTEIN BINDING; SHEEP; VIRUS INTERNALIZATION; VIRUS REPLICATION;

BOVINAE; HEPATITIS C VIRUS; OVIS ARIES;

EID: 84879058795     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-199     Document Type: Article

References (42)

1. Global challenges in liver disease. Williams R, Hepatology 2006 44 521 526 10.1002/hep.21347 16941687
2. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Nguyen MH, Keeffe EB, Clin Gastroenterol Hepatol 2005 3 97 S101 16234071
3. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Hepatology 2000 32 111 115 10869297
4. Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M, Khan A, J Med Virol 2009 81 1015 1023 10.1002/jmv.21492 19382263
5. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB, J Viral Hepatol 2007 14 107 115 10.1111/j.1365-2893.2006.00785.x
6. Lactoferrin structure and functions. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J, Adv Exp Med Biol 2008 606 163 194 10.1007/978-0-387-74087-4-6 18183929
7. Lactoferrin: a modulator of immune and inflammatory responses. Legrand D, Elass E, Carpentier M, Mazurier J, Cell Mol Life Sci 2005 62 2549 2559 10.1007/s00018-005-5370-2 16261255
8. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. Marchetti M, Pisani S, Antonini G, Valenti P, Seganti L, Orsi N, BioMetals 1998 11 89 94 10.1023/A:1009217709851 9542061
9. Antiviral activity of lactoferrin. Valenti P, Marchetti M, Superti F, Amendolia MG, Puddu P, Gessani S, Borghi P, Belardelli F, Antonini G, Seganti SL, Adv Exp Med Biol 1998 443 199 203 9781359
10. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, Kato N, Biochem Biophys Res Commun 1998 245 549 553 10.1006/bbrc.1998.8481 9571193
11. Hepatitis C virus envelope proteins bind lactoferrin. Yi M, Kaneko S, Yu DY, Murakami S, J Virol 1997 71 5997 6002 9223490
12. Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. Redwan EM, Tabll A, J Immunoassay Immunochem 2007 28 267 277 10.1080/15321810701454839 17613672
13. Potential activity of camel milk-amylase and lactoferrin against hepatitis c virus infectivity in HepG2 and lymphocytes. EL-Fakharany EM, Tabll A, Redwan EM, Hepat Mon 2008 8 101 109
14. Inhibitory Effects of Native/Recombinant Full-Length Camel Lactoferrin and its N/C lobes on Hepatitis C Virus Infection of Huh7.5 Cells. Liao Y, El-Fakkarany E, Lönnerdal B, Redwan EM, J Med Microbiol 2012 61 375 383 10.1099/jmm.0.033894-0 22052996
15. Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma. EL-Fakharany EM, El-baky NA, Haroun BM, Sánchez L, Redwan NA, Redwan EM, J Virol 2012 9 201 1 9
16. Anti-HSV activity of lactoferricin analogues is only partly related to their affi nity for heparan sulfate. Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal O, Antiviral Res 2004 61 101 109 10.1016/j.antiviral.2003. 09.001 14670583
17. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparin sulphate at the cell surface. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ, J Med Virol 2004 74 2 262 271 10.1002/jmv.20171 15332275
18. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Marchetti M, Trybala E, Superti F, Johansson M, Bergstöm T, Virology 2004 318 405 413 10.1016/j.virol.2003.09.029 14972565
19. Antiviral activities of lactoferrin. van der Strate BWA, Beljaars L, Molena G, Harmsen MC, Meijer DKF, Antiviral Res 2001 52 225 239 10.1016/S0166-3542(01)00195-4 11675140
20. Examination of the Activity of Camel Milk Casein against Hepatitis C Virus (Genotype-4a) and Its Apoptotic Potential in Hepatoma and HeLa Cell Lines. Almahdy O, EL-Fakharany EM, EL-Dabaa E, Ng TB, Redwan EM, Hepas Mon 2011 11 724 730 10.5812/kowsar.1735143X.1367
21. Cumulative updating of approved biopharmaceuticals. Redwan EM, Hum Antibodies 2007 16 137 158 18334749
22. Animal-derived pharmaceutical proteins. Redwan EM, J Immunoassay Immunochem 2009 30 262 290 10.1080/15321810903084400 19591041
23. Real-time RT-PCR for quantitation of hepatitis C virus RNA. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu X, Ho W, J Virol Meth 2002 102 119 128 10.1016/S0166-0934(02)00007-1
24. Flow cytometric detection of hepatitis C virus antigens in infected pripheral blood leukocytes: binding and entry. EL-Awady MK, Tabll AA, Redwan EM, Youssef S, Omran MH, El-Demellawy M, W J Gastroenterol 2005 11 5203 5208
25. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Ikeda M, Nozaki A, Sugiyama K, Tanaka T, Naganuma A, Tanaka K, Sekihara H, Shimotohno K, Saito M, Kato N, Virus Res 2000 66 51 63 10.1016/S0168-1702(99)00121-5 10653917
26. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. Nozaki A, Ikeda M, Naganuma A, Nakamura T, Inudoh M, Tanaka K, Kato N, J Biol Chem 2003 278 10162 10173 10.1074/jbc.M207879200 12522210
27. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Drobni P, Naslund J, Evander M, Antiviral Res 2004 64 1 63 68 15451180
28. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara H, Hepatol Res 2002 4 3 228 235
29. Involvement of bovine lactoferrin moieties in the inhibition of herpes simplex virus type 1 infection. Seganti L, Di Biase AM, Rega B, De Giulio B, Nicoletti M, Antonini G, Valenti P, Int J Immunopathol Pharmacol 2001 14 2 71 79 12604021
30. Inhibition of poliovirus type 1 infection by iron-, manganeseand zinc-saturated lactoferrin. Marchetti M, Superti F, Ammendolia MG, Rossi P, Valenti P, Seganti L, Med Microbiol Immunol 1999 187 199 204 10.1007/s004300050093 10363676
31. Effect of antimicrobial factors in human milk on rhinoviruses and milk-borne cytomegalovirus in vitro. Clarke NM, May JT, J Med Microbiol 2000 49 719 723 10933257
32. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. Lin TY, Chu C, Chiu CH, J Infect Dis 2002 186 1161 1164 10.1086/343809 12355368
33. Camel lactoferrin, a transferrin-cumlactoferrin: crystal structure of camel apolactoferrin at 2.6 Å resolution and structural basis of its dual role. Khan JA, Kumar P, Paramasivam M, Yadav RS, Sahani MS, Sharma S, J Mol Biol 2001 309 751 761 10.1006/jmbi.2001.4692 11397094
34. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Konishi M, Iwasa M, Yamauchi K, Sugimoto R, Fujita N, Kobayashi Y, Hepatol Res 2006 36 27 32 10.1016/j.hepres.2006.06.005 16857423
35. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Laemmli UK, Nature 1970 227 680 685 10.1038/227680a0 5432063
36. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Bradford MM, J Anal Biochem 1976 72 248 254 10.1016/0003-2697(76)90527-3
37. Simple, sensitive and quick protocol to detect less than 1ng of bacterial lipopolysaccharide. Redwan E, Prep Biochem Biotechnol 2012 42 1 12 10.1080/10826068.2011.552145 22239704
38. Oyster Mushroom Laccase Inhibits Hepatitis C Virus Entry into Peripheral Blood Cells and Hepatoma Cells. El-Fakharany EM, Haroun BM, Ng TB, Redwan ER, Protein Pept Lett 2010 17 8 1031 1039 10.2174/092986610791498948 20156183
39. Efficacy comparison of gel-based, membrane and glass array techniques to detect human antibodies isotypes among the Egyptian HCV-patients. EL-Baky NA, Omar SH, EL-Badry H, Redwan EM, Hum Antibodies 2008 17 63 71 19029663
40. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Mosmann T, J Immunol Methods 1983 65 1-2 55 63 6606682
41. The anti-cancer activity of human consensus interferon-alpha synthesized in cell-free system. El-Baky NA, Omar SH, Redwan EM, Protein Express Purif 2011 80 61 67 10.1016/j.pep.2011.07.003
42. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. EL-Awady MK, Tabll AA, El-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, Be-D NG, Redwan E-RM, El-Demellawy M, Omran MH, El-Garf WT, Goueli SA, W J Gastroenterol 2006 12 4836 4842